GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avecho Biotechnology Ltd (OTCPK:AVEFF) » Definitions » Capex-to-Operating-Cash-Flow

AVEFF (Avecho Biotechnology) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Avecho Biotechnology Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Avecho Biotechnology's Capital Expenditure for the six months ended in Dec. 2024 was $0.00 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2024 was $-2.12 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Avecho Biotechnology Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Avecho Biotechnology's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avecho Biotechnology Capex-to-Operating-Cash-Flow Chart

Avecho Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Avecho Biotechnology Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Avecho Biotechnology's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Avecho Biotechnology's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avecho Biotechnology's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Avecho Biotechnology's Capex-to-Operating-Cash-Flow falls into.


;
;

Avecho Biotechnology Capex-to-Operating-Cash-Flow Calculation

Avecho Biotechnology's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -2.514
=N/A

Avecho Biotechnology's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -2.115
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avecho Biotechnology  (OTCPK:AVEFF) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Avecho Biotechnology Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Avecho Biotechnology's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Avecho Biotechnology Business Description

Traded in Other Exchanges
Address
Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology Headlines